- Home
- KAVL vs TSBX Comparison
KAVL vs TSBX Comparison
Compare KAVL & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- TSBX
- Stock Information
- Founded
- KAVL 1998
- TSBX 2015
- Country
- KAVL United States
- TSBX United States
- Employees
- KAVL N/A
- TSBX N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- TSBX
- Sector
- KAVL Health Care
- TSBX
- Exchange
- KAVL Nasdaq
- TSBX Nasdaq
- Market Cap
- KAVL 7.9M
- TSBX 7.7M
- IPO Year
- KAVL N/A
- TSBX 2023
- Fundamental
- Price
- KAVL $0.49
- TSBX $0.36
- Analyst Decision
- KAVL
- TSBX Buy
- Analyst Count
- KAVL 0
- TSBX 3
- Target Price
- KAVL N/A
- TSBX $4.75
- AVG Volume (30 Days)
- KAVL 27.8K
- TSBX 859.0K
- Earning Date
- KAVL 06-10-2025
- TSBX 08-13-2025
- Dividend Yield
- KAVL N/A
- TSBX N/A
- EPS Growth
- KAVL N/A
- TSBX N/A
- EPS
- KAVL N/A
- TSBX N/A
- Revenue
- KAVL $1,698,426.00
- TSBX N/A
- Revenue This Year
- KAVL N/A
- TSBX N/A
- Revenue Next Year
- KAVL N/A
- TSBX N/A
- P/E Ratio
- KAVL N/A
- TSBX N/A
- Revenue Growth
- KAVL N/A
- TSBX N/A
- 52 Week Low
- KAVL $0.46
- TSBX $0.29
- 52 Week High
- KAVL $3.02
- TSBX $3.00
- Technical
- Relative Strength Index (RSI)
- KAVL 36.39
- TSBX 44.06
- Support Level
- KAVL $0.49
- TSBX $0.35
- Resistance Level
- KAVL $0.56
- TSBX $0.38
- Average True Range (ATR)
- KAVL 0.03
- TSBX 0.03
- MACD
- KAVL -0.00
- TSBX -0.00
- Stochastic Oscillator
- KAVL 1.82
- TSBX 3.67
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.